drugset / Trial / NCT00641381

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT00641381

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells that were collected from the patient's blood are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This clinical trial is studying the side effects of giving high-dose carmustine, etoposide, and cyclophosphamide together with a stem cell transplant and to see how well it works in treating patients with HIV-associated lymphoma.

Timeline

Start
2000-05-10
Primary completion
2026-02-13
Completion
2026-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 100 mg/kg
Subject Etoposide Small molecule 60 mg/kg
Subject carmustine Small molecule 150 mg/m2 Intravenous

Indications